Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Executive VP, Global R&D | May 17, 2022 | May 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date May 17, 2022 · Filed May 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,386.514 |
Reported balance
After 2022-05-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-17 · Sale · Disposed 130,000 · Balance 1,386.514 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F3: The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2022 Filed May 19, 2022 11:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 130,000 | $8.22 | $1,068,067.00 |
DisclosureSEC source: 0001209191-22-030308 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,386.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 8,941 | $7.37 | $65,865.66 |
DisclosureSEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 6 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,086.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 23,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017046 · doc4.xml · derivative · entry 10 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,293 Underlying: Ordinary Shares · 23,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F10 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 having vested on March 5, 2022, 23,764 vesting on each of March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025. F10 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 having vested on March 5, 2022, 23,764 vesting on each of March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 23,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 5 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,027.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 140,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017046 · doc4.xml · derivative · entry 9 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,750 Underlying: Ordinary Shares · 140,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F9 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 35,187 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 35,189 vesting on March 4, 2026. F9 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 35,187 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 35,189 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 18,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017046 · doc4.xml · derivative · entry 8 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,906 Underlying: Ordinary Shares · 18,905 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 18,905 having vested on each of March 4, 2021 and March 4, 2022, and 18,906 vesting on March 4, 2023. F8 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 18,905 having vested on each of March 4, 2021 and March 4, 2022, and 18,906 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 51,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017046 · doc4.xml · derivative · entry 7 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 51,488 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F7 · derivative.expiration_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,618 | $7.48 | $49,519.19 |
DisclosureSEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 4 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,263.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 18,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,881.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 18,020 | $7.48 | $134,834.65 |
DisclosureSEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,976.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 51,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,996.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:47 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 21,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014469 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,366 Underlying: Ordinary Shares · 21,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 21,682 having vested on each of February 28, 2021 and February 28, 2022, 21,682 vesting on February 28, 2023 and 21,684 vesting on February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 21,682 having vested on each of February 28, 2021 and February 28, 2022, 21,682 vesting on February 28, 2023 and 21,684 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:47 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 7,590 | $8.14 | $61,799.30 |
DisclosureSEC source: 0001209191-22-014469 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,508.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:47 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 21,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014469 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,098.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 16,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008415 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 16,121 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 having vested on each of February 9, 2020 and February 9, 2021 and 16,121 having vested on February 9, 2022. F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 having vested on each of February 9, 2020 and February 9, 2021 and 16,121 having vested on February 9, 2022. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,116 | $9.06 | $55,412.18 |
DisclosureSEC source: 0001209191-22-008415 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,416.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 16,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-008415 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,532.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 51,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008415 · doc4.xml · derivative · entry 4 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,488 Underlying: Ordinary Shares · 51,488 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. F7 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 50,860 | $9.95 | $506,021.40 |
DisclosureSEC source: 0001209191-21-051075 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,411.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.91 to $10.00, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2021 Filed May 13, 2021 11:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 37,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032252 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 37,884 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021. F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 11, 2021 Filed May 13, 2021 11:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 19,066 | $10.22 | $194,829.73 |
DisclosureSEC source: 0001209191-21-032252 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,271.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.205 to $10.230, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2021 Filed May 13, 2021 11:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 37,884 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-032252 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,337.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 95,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018518 · doc4.xml · derivative · entry 4 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,057 Underlying: Ordinary Shares · 95,057 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025. F7 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 18,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018518 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,811 Underlying: Ordinary Shares · 18,905 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023. F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 9,515 | $10.57 | $100,536.44 |
DisclosureSEC source: 0001209191-21-018518 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,453.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.690, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 18,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-018518 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,968.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 50,000 | $10.82 | $540,890.00 |
DisclosureSEC source: 0001209191-21-017758 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,063.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.790 to $10.870, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 10,912 | $10.83 | $118,185.69 |
DisclosureSEC source: 0001209191-21-015842 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,063.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.78 to $11.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 21,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015842 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,048 Underlying: Ordinary Shares · 21,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 21,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-015842 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,975.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,098 | $11.12 | $23,335.84 |
DisclosureSEC source: 0001209191-21-011244 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,293.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.105 to $11.135, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011244 · doc4.xml · derivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,355 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021. F6 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011244 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,391.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 37,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009633 · doc4.xml · derivative · entry 6 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,884 Underlying: Ordinary Shares · 37,884 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F9 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on May 11, 2021. F9 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on May 11, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 16,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009633 · doc4.xml · derivative · entry 5 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,121 Underlying: Ordinary Shares · 16,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F8 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 23,639 | $12.69 | $300,085.29 |
DisclosureSEC source: 0001209191-21-009633 · doc4.xml · nonDerivative · entry 4 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,036.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 5,857 | $12.69 | $74,351.69 |
DisclosureSEC source: 0001209191-21-009633 · doc4.xml · nonDerivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,675.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 67,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009633 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,532.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units. F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 16,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009633 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,680.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 266 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020163 · doc4.xml · derivative · entry 6 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 266 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020. F7 · derivative.expiration_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 748 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020163 · doc4.xml · derivative · entry 5 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 748 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020. F6 · derivative.expiration_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 134 | $7.16 | $959.91 |
DisclosureSEC source: 0001209191-20-020163 · doc4.xml · nonDerivative · entry 4 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,560.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 380 | $7.16 | $2,722.13 |
DisclosureSEC source: 0001209191-20-020163 · doc4.xml · nonDerivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,694.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 266 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-020163 · doc4.xml · nonDerivative · entry 2 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,074.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:33 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 748 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-020163 · doc4.xml · nonDerivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,808.514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 12:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 86,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014849 · doc4.xml · derivative · entry 1 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,730 Underlying: Ordinary Shares · 86,730 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024. F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 17,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009879 · doc4.xml · derivative · entry 6 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020. F7 · derivative.expiration_date: Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009879 · doc4.xml · derivative · entry 5 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,355 Underlying: Ordinary Shares · 5,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021. F6 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 8,825 | $12.14 | $107,154.92 |
DisclosureSEC source: 0001209191-20-009879 · doc4.xml · nonDerivative · entry 4 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,060.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.962 to $12.2800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,647 | $12.14 | $32,140.40 |
DisclosureSEC source: 0001209191-20-009879 · doc4.xml · nonDerivative · entry 3 Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,885.514 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.962 to $12.2800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.